Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cats A, Jansen EPM, Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet 2018; 19: 616-28. 10.1016/S1470-2045(18)30132-3CatsAJansenEPMGriekenNCTSikorskaKLindPNordsmarkMet alChemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trialLancet201819616–2810.1016/S1470-2045(18)30132-3Open DOISearch in Google Scholar
Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatine for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-lable, randomised phase 3 trial. Lancet 2014; 15: 1389-96. 10.1016/S1470-2045(14)70473-5NohSHParkSRYangHKChungHCChungIJKimSWet alAdjuvant capecitabine plus oxaliplatine for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-lable, randomised phase 3 trialLancet2014151389–9610.1016/S1470-2045(14)70473-5Open DOISearch in Google Scholar
Reece-Smith AM, Saunders JH, Soomro IN, Bowman CR, Duffy JP, Kaye PV, et al. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Ann R Coll Surg Engl 2017; 99: 378-84. 10.1308/rcsannReece-SmithAMSaundersJHSoomroINBowmanCRDuffyJPKayePVet alPostoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinomaAnn R Coll Surg Engl201799378–8410.1308/rcsannOpen DOISearch in Google Scholar
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46. 10.1056/NEJMoa073149CunninghamDStarlingNRaoSIvesonTNicolsonMCoxonFet alCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med200835836–4610.1056/NEJMoa073149Open DOISearch in Google Scholar
Yehou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicentre phase III trial. J Clin Oncol 2011; 29: 1715-21. 10.1200/JCO.2010.33.0597YehouMBoigeVPignonJPConroyTBoucheOLebretonGet alPerioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicentre phase III trialJ Clin Oncol2011291715–2110.1200/JCO.2010.33.0597Open DOISearch in Google Scholar
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20. 10.1056/NEJMoa0722SakuramotoSSasakoMYamaguchiTKinoshitaTFujiiMNashimotoAet alAdjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidineN Engl J Med20073571810–2010.1056/NEJMoa0722Open DOISearch in Google Scholar
Nakajima T, Fujii M. What make differences in the outcome in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20: 11567-73. 10.3748/wjg.v20.i33.11567NakajimaTFujiiMWhat make differences in the outcome in the outcome of adjuvant treatments for resected gastric cancer?World J Gastroenterol20142011567–7310.3748/wjg.v20.i33.11567Open DOISearch in Google Scholar
Toneto MG, Viola L. Current status of the multidisciplinary treatment of gastric adenocarcinoma. [English, Portuguese]. Arq Bras Cir Dig 2018; 31: 1-4. 10.1590/0102-672020180001e1373TonetoMGViolaLCurrent status of the multidisciplinary treatment of gastric adenocarcinoma[English, Portuguese]. Arq Bras Cir Dig2018311–410.1590/0102-672020180001e1373Open DOISearch in Google Scholar
Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018; 9: 560-72. 10.21037/jgo.2018.03.01ChuangJGongJKlempnerSJWooYChaoJRefining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classificationJ Gastrointest Oncol20189560–7210.21037/jgo.2018.03.01Open DOISearch in Google Scholar
Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative therapy of oesophagogastric adenocarcinoma and future directions. Gastroenterol Res Pract 2017; 1-6. 10.1155/2017/5651903BoseKFranckCMüllerMNCanbayALinkAVeneritoMPerioperative therapy of oesophagogastric adenocarcinoma and future directionsGastroenterol Res Pract20171–610.1155/2017/5651903Open DOISearch in Google Scholar
Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet 2017; 18: 1249-60. 10.1016/S1470-2045(17)30447-3AldersonDCunninghamDNankivellMBlazebyJMGriffinSMCrellinANeoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialLancet2017181249–6010.1016/S1470-2045(17)30447-3Open DOISearch in Google Scholar
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, DiCostanzo F, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 2014; 25: 1373-78. 10.1093/annonc/mdu146BajettaEFlorianiIDiBartolomeo MLabiancaRFalconeADiCostanzoFet alRandomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancerAnn Oncol2014251373–7810.1093/annonc/mdu146Open DOISearch in Google Scholar
Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III Trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015; 33: 3130-3136. 10.1200/JCO.2014.58.3930ParkSHSohnTSLeeJLimDHHongMEKimKMet alPhase III Trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analysesJ Clin Oncol2015333130–313610.1200/JCO.2014.58.3930Open DOISearch in Google Scholar
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30. 10.1056/NEJMoa010187MacdonaldJSSmalleySRBenedettiJHundahlSAEstesNCStemmermannGNet alChemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med2001345725–3010.1056/NEJMoa010187Open DOISearch in Google Scholar
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23. 10.1007/s10120-011-0042-4Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines2010(ver. 3)Gastric Cancer201114113–2310.1007/s10120-011-0042-4Open DOISearch in Google Scholar
Oblak I, Skoblar Vidmar M, Anderluh F, Velenik V, Jeromen A, But Hadzic J. Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma. Radiol Oncol 2014; 48: 189-96. 10.2478/raon-2013-0065OblakISkoblarVidmar MAnderluhFVelenikVJeromenAButHadzic JCapecitabine in adjuvant radiochemotherapy for gastric adenocarcinomaRadiol Oncol201448189–9610.2478/raon-2013-0065Open DOISearch in Google Scholar
Lee KY, Noh SH, Hyung WJ, Lee JH, Lah KH, Choi SH, et al. Impact of splenectomy for lymph node dissection on long-term outcome in gastric cancer. Ann Surg Oncol 2001; 8: 402-6. PMID: 11407513LeeKYNohSHHyungWJLeeJHLahKHChoiSHet alImpact of splenectomy for lymph node dissection on long-term outcome in gastric cancerAnn Surg Oncol20018402–61140751310.1007/s10434-001-0402-0Search in Google Scholar
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrics 1983; 70: 41-55.RosenbaumPRRubinDBThe central role of the propensity score in observational studies for causal effectsBiometrics19837041–5510.21236/ADA114514Search in Google Scholar
Li M. Using the propensity score method to estimate causal effects: a review and practical guide. Organ Res Methods 2012; 00: 1-39. 10.1177/1094428112447816LiMUsing the propensity score method to estimate causal effects: a review and practical guideOrgan Res Methods2012001–3910.1177/1094428112447816Open DOISearch in Google Scholar
Hartgrink HH, van de Velde CJH, Putter H, Bonekamp JJ, Kranenbarg K, Songun I, et al. Extended lymph-node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-77. 10.1200/JCO.2004.08.026HartgrinkHHvan deVelde CJHPutterHBonekampJJKranenbargKSongunIet alExtended lymph-node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trialJ Clin Oncol2004222069–7710.1200/JCO.2004.08.026Open DOISearch in Google Scholar
Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AFY, et al. Nodal dissection for patients with gastric cancer: a randomized control trial. Lancet Oncol 2006; 7: 309-15. 10.1016/S1470-2045(06)70623-4WuCWHsiungCALoSSHsiehMCChenJHLiAFYet alNodal dissection for patients with gastric cancer: a randomized control trialLancet Oncol20067309–1510.1016/S1470-2045(06)70623-4Open DOISearch in Google Scholar
Zhang Y, Tian S. Does D2 plus para-aortic nodal dissection surgery offer a better survival outcome compared to D2 surgery only for gastric cancer consistently? A definite result based on a hospital population of nearly two decades. Scand J Surg 2013; 102: 251-7. 10.1177/1457496913491343ZhangYTianSDoes D2 plus para-aortic nodal dissection surgery offer a better survival outcome compared to D2 surgery only for gastric cancer consistently? A definite result based on a hospital population of nearly two decadesScand J Surg2013102251–710.1177/1457496913491343Open DOISearch in Google Scholar
